Latest Cancer Therapy News

Imugene Limited has received a $5.87 million R&D tax refund, reinforcing its capacity to advance clinical trials in immuno-oncology. This funding milestone supports the development of its innovative cancer therapies, including CAR T cell treatments and oncolytic virotherapy.

Prescient Therapeutics has opened a Share Purchase Plan to raise up to $7 million, offering shareholders discounted shares to fund the Phase 2 development of its targeted cancer therapy PTX-100.

Prescient Therapeutics has launched a $7 million Share Purchase Plan at a notable discount to fund the next phase of clinical trials for its promising PTX-100 cancer therapy. The capital raise aims to accelerate progress toward regulatory approval and patient access.

Percheron Therapeutics has licensed HMBD-002, a promising immuno-oncology monoclonal antibody targeting VISTA, from Hummingbird Bioscience, marking a strategic pivot after recent setbacks. The company plans to initiate phase II trials in 2026, aiming to advance this novel cancer therapy toward commercialisation.

Radiopharm Theranostics has inked a clinical supply agreement with Cyclotek to support its Phase 1 trial of RAD 402, a novel radiotherapeutic targeting prostate cancer, set to commence in Australia in late 2025.

INOVIQ Limited has announced a breakthrough in its cancer treatment program, with its CAR-exosome therapy killing 88% of triple negative breast and lung cancer cells in laboratory studies. This innovation could pave the way for faster, safer, and more accessible cancer therapies.

Radiopharm Theranostics has unveiled encouraging preclinical results for its Lu177-B7H3 monoclonal antibody, RV01, paving the way for a mid-2025 Investigational New Drug submission and a Phase 1 trial later that year.

Chimeric Therapeutics has progressed its CHM CDH17 CAR-T cell therapy clinical trial to Dose Level 2 after completing Dose Level 1 with no safety concerns, showing encouraging early signs of activity in advanced gastrointestinal cancers.

ITM Isotope Technologies Munich SE and Radiopharm Theranostics have entered a strategic supply agreement for the critical radioisotope Lutetium-177, underpinning Radiopharm’s clinical development of targeted cancer therapies.

Algorae Pharmaceuticals has partnered with Peter MacCallum Cancer Centre to validate AI-predicted drug combinations across multiple cancer types, aiming to accelerate its oncology pipeline development.

Patrys Limited advances its PAT-DX3 therapy development for inflammatory diseases while navigating cash flow challenges and pursuing partnerships to sustain operations.

Radiopharm Theranostics' RAD 101 radiotracer demonstrates high sensitivity in detecting brain metastases using a novel PET-mpMRI approach, with a Phase 2b trial now recruiting in the US.